Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$134.41
+1.8%
$131.69
$107.11
$141.23
$233.71B0.77.88 million shs4.99 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$103.22
+0.3%
$103.54
$75.00
$108.94
$152.83B0.667.57 million shs5.08 million shs
Cynosure, Inc. stock logo
CYNO
Cynosure
$66.00
$0.00
$39.90
$66.65
N/AN/A1.24 million shsN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$470.08
+0.1%
$516.52
$425.00
$616.00
$168.51B1.592.24 million shs1.45 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%+5.57%+0.57%+0.68%+22.25%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.00%-2.07%-0.55%+0.34%+39.90%
Cynosure, Inc. stock logo
CYNO
Cynosure
0.00%0.00%0.00%0.00%0.00%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.00%-2.70%-10.64%-12.39%+4.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9086 of 5 stars
2.54.04.24.54.21.72.5
Boston Scientific Corporation stock logo
BSX
Boston Scientific
4.5494 of 5 stars
3.53.00.04.23.52.51.3
Cynosure, Inc. stock logo
CYNO
Cynosure
N/AN/AN/AN/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.9311 of 5 stars
4.34.00.04.04.22.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.91
Moderate Buy$144.477.49% Upside
Boston Scientific Corporation stock logo
BSX
Boston Scientific
3.04
Buy$117.5013.83% Upside
Cynosure, Inc. stock logo
CYNO
Cynosure
0.00
N/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.63
Moderate Buy$595.9526.78% Upside

Current Analyst Ratings Breakdown

Latest CYNO, ABT, ISRG, and BSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$121.00 ➝ $124.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$130.00 ➝ $135.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$110.00 ➝ $118.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$118.00 ➝ $124.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00 ➝ $125.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$125.00 ➝ $133.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$117.00 ➝ $123.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$547.00 ➝ $585.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$575.00 ➝ $595.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$590.00 ➝ $600.00
(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.58$6.59 per share20.40$27.62 per share4.87
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$16.75B9.13$3.65 per share28.25$14.93 per share6.91
Cynosure, Inc. stock logo
CYNO
Cynosure
N/AN/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.35B20.18$7.99 per share58.85$46.41 per share10.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.9816.8423.462.5532.43%18.32%10.71%10/15/2025 (Estimated)
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$1.85B$1.6861.4431.962.4813.55%19.21%10.62%10/22/2025 (Estimated)
Cynosure, Inc. stock logo
CYNO
Cynosure
N/AN/A0.00N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$7.1765.5661.614.9328.51%14.56%12.93%10/16/2025 (Estimated)

Latest CYNO, ABT, ISRG, and BSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.72$0.75+$0.03$0.53$4.89 billion$5.06 billion
7/22/2025Q2 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.93$2.19+$0.26$1.81$2.35 billion$2.44 billion
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.26$1.26N/A$1.01$11.01 billion$11.14 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.76%N/A29.57%54 Years
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Cynosure, Inc. stock logo
CYNO
Cynosure
N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A

Latest CYNO, ABT, ISRG, and BSX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.25
1.82
1.30
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.49
1.37
0.82
Cynosure, Inc. stock logo
CYNO
Cynosure
N/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
5.17
4.18

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
Cynosure, Inc. stock logo
CYNO
Cynosure
N/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.50%
Cynosure, Inc. stock logo
CYNO
Cynosure
2.90%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
53,0001.48 billion1.47 billionOptionable
Cynosure, Inc. stock logo
CYNO
Cynosure
N/AN/AN/ANot Optionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
15,638358.48 million355.97 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$134.41 +2.35 (+1.78%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$134.40 -0.01 (0.00%)
As of 08/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$103.22 +0.26 (+0.25%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$103.65 +0.43 (+0.42%)
As of 08/8/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Cynosure stock logo

Cynosure NASDAQ:CYNO

Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$470.08 +0.27 (+0.06%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$470.60 +0.52 (+0.11%)
As of 08/8/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.